ACE2 Chimeric Protein Compositions for Mucosal Viral Entry Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to prevent and treat coronavirus infections, particularly SARS-CoV-2, due to the limitations of facemasks and the potential risks of vaccine mutations, with a focus on developing compositions that target the angiotensin-converting enzyme 2 (ACE2) receptor for viral entry.
Innovation Solution
A chimeric protein comprising an ACE2 extracellular binding domain and a positively charged mucoadhesive peptide fragment is used to attach to mucosal surfaces, blocking viral entry and activating the complement pathway to neutralize the virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If facemasks are used as the first line of defense, then passive barrier protection is provided, but efficacy is imperfect and does not actively prevent viral entry
Solution Approach 1:
The patent introduces ACE2-binding peptides as intermediary molecules that mediate between the protective agent and the virus. These peptides bind to the spike protein of coronaviruses, acting as a molecular intermediary that blocks viral entry without requiring physical contact or systemic administration, thereby improving protection efficacy while maintaining ease of use through topical application
Solution Approach 2:
The invention applies preliminary action by administering ACE2-binding peptides to mucosal surfaces before viral exposure. The peptides are positioned in advance at the site of viral entry (mucosal surfaces), creating a pre-established blocking mechanism that actively prevents viral attachment and entry, transforming passive protection into active prevention
2Reliability
If SARS-CoV-2 vaccines are developed, then immune response is stimulated, but viral gene mutations and antibody-dependent enhancement pose risks
Solution Approach 1:
The patent extracts the essential blocking function from the complex vaccine-induced immune response and isolates it into a simplified ACE2-binding peptide mechanism. By taking out only the critical receptor-binding blocking activity and removing the complexities of whole-virus or protein-subunit vaccines, the invention creates a focused intervention that targets viral entry without triggering the problematic immune responses associated with vaccines
Solution Approach 2:
The invention employs short-living ACE2-binding peptides that provide temporary but effective protection at mucosal surfaces. These peptides are administered topically and provide localized protection without requiring long-term systemic immunity, allowing for flexible reapplication and avoiding the persistence issues that contribute to antibody-dependent enhancement
3Reliability
If inhibitory polypeptides targeting the RBD of SARS-CoV-2 spike protein are developed, then viral entry is blocked, but systemic administration is required which increases complexity
Solution Approach 1:
The patent applies local quality by concentrating the protective function at the specific site of viral entry - the mucosal surfaces. The ACE2-binding peptides are administered topically to nasal, oral, or respiratory mucosa, providing localized high-concentration protection exactly where the virus attempts to enter, eliminating the need for systemic distribution and reducing overall complexity
Solution Approach 2:
The invention segments the protective function from the systemic circulation requirement. Instead of requiring whole-body distribution of inhibitory polypeptides, the patent divides the protection into localized mucosal applications, where small ACE2-binding peptides can be effectively delivered and retained through mucoadhesive properties, simplifying the administration pathway
4Reliability
If ACE2 inhibitory peptides are used, then viral entry is prevented, but mucosal attachment stability needs enhancement
Solution Approach 1:
The patent creates composite structures by combining ACE2-binding peptides with mucoadhesive moieties. This composite material integrates the viral-entry-blocking function of ACE2-binding peptides with the mucosal-retention capability of mucoadhesive groups, achieving both reliable viral prevention and extended mucosal residence time through a single integrated molecule
Solution Approach 2:
The invention merges two distinct functions - ACE2 binding and mucosal adhesion - into a single chimeric peptide molecule. The ACE2-binding domain provides viral entry prevention while the attached mucoadhesive group provides stable mucosal attachment, combining these functions synergistically to achieve both high reliability and prolonged duration of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric protein effectively prevents and treats coronavirus infections by enhancing mucosal attachment and activating the complement pathway, providing protection against various variants and reducing the need for systemic administration.
Implementation Method 1
a mucoadhesive peptide fragment comprising at least about 5 positively charged amino acid residues, wherein the mucoadhesive peptide fragment facilitates attachment of the chimeric protein to a mucosa
Implementation Method 2
ACE2 mediates viral entry into cells, via binding of the S protein through the S1 subunit of the RBD. Therefore, ACE2 inhibitory peptides represent promising therapeutics to prevent coronavirus infection
Implementation Method 3
blocking viral entry and activating the complement pathway to neutralize the virus
Data Source
AI summary
The present application relates to compositions for preventing or treating infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety comprising an extracellular binding domain (EBD) of an angiotensin-converting enzyme 2 (ACE2) protein or a fragment thereof that specifically binds to an S protein, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating a viral infection in an individual, such as a coronavirus infection.